preclinical phase of rheumatoid arthritis
Conditions
Brief summary
Number of patients with development of arthritis at week 48
Detailed description
Number of patients with development of arthritis at week 24, Fulfillment of the ACR/EULAR 2010 RA classification criteria, Ultrasound: number of patients without signs of PD synovitis or PD tenosynovitis at week 24 and week 48 compared to baseline and compared within both groups, Safety: (S)AE, Subjective (SACRAH, sMHQ) and objective (moberg pick up test (MPUT)) hand function, Change in anti CCP2 antibody levels (RE/ml)
Interventions
DRUGBaricitinib-Placebo ident appearance
DRUGBARICITINIB
Sponsors
Universitaetsklinikum Erlangen AöR
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with development of arthritis at week 48 | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with development of arthritis at week 24, Fulfillment of the ACR/EULAR 2010 RA classification criteria, Ultrasound: number of patients without signs of PD synovitis or PD tenosynovitis at week 24 and week 48 compared to baseline and compared within both groups, Safety: (S)AE, Subjective (SACRAH, sMHQ) and objective (moberg pick up test (MPUT)) hand function, Change in anti CCP2 antibody levels (RE/ml) | — |
Countries
Germany
Outcome results
None listed